ABLYNX ANNOUNCES 2011 FULL YEAR RESULTS (Ablynx)

Publicerad 22 Feb 2012 av BolagsFakta.se

ABLYNX ANNOUNCES 2011 FULL YEAR RESULTS (Ablynx)

Strong year of progress at Ablynx as first Nanobody® reaches clinical proof-of-concept GHENT, Belgium, 22nd February 2012 - Ablynx (Euronext Brussels: ABLX), the Belgian-based biopharmaceutical company focused on the discovery and development of Nanobodies for the treatment...

LÄS HELA ARTIKELN

Dela med andra

Vad andra rapporterar om samma händelse

Medivir: Financial Statement, 1 January – 31 De... [ Publicerad 23 Feb 2012 av BolagsFakta ]

Telecom Egypt Goes Live With Ascade"s Routing S... [ Publicerad 23 Feb 2012 av BolagsFakta ]

DryShips sells dispute ships [ Publicerad 23 Feb 2012 av BolagsFakta ]

NOL suffers Q4 bloodbath [ Publicerad 23 Feb 2012 av BolagsFakta ]

ConocoPhillips primes Browse bit [ Publicerad 23 Feb 2012 av BolagsFakta ]

Iran offsets oil slowdown concerns [ Publicerad 23 Feb 2012 av BolagsFakta ]

Industry ire at Obama tax proposals [ Publicerad 23 Feb 2012 av BolagsFakta ]

Rising labor costs could see China import workers [ Publicerad 23 Feb 2012 av BolagsFakta ]

Full Year Report 2011 [ Publicerad 23 Feb 2012 av BolagsFakta ]

Klövern AB (publ) : Issues a three-year bond lo... [ Publicerad 23 Feb 2012 av BolagsFakta ]

Relaterade händelser

Publicerad 04 Apr 2012 - uppdaterad 04 Apr 2012 - 1 Dokument

Novartis AG

ABLYNX"S PARTNER SHOWS THAT A NANOBODY CAN ELICIT SUPERIOR ANTI-TUMOUR EFFICACY COMPARED TO CONVENTIONAL MONOCLONAL ANTIBODY APPROACHES

- Ablynx [Euronext Brussels: ABLX] today noted that a paper on a novel tetrameric Nanobody® agonist (TAS266) targeting Death Receptor 5 (DR5), a key receptor target on cancer cells across a number of tumour types, was presented at the American Association ... [ Publicerad 04 Apr 2012 av BolagsFakta ]

Entiteter: Ablynx, Receptor, agonist, Novartis AG, Edwin Moses

Publicerad 20 Mar 2012 - uppdaterad 20 Mar 2012 - 1 Dokument

Boehringer Ingelheim GmbH

ABLYNX ANNOUNCES AN EXTENSION OF ITS GLOBAL STRATEGIC NANOBODY ALLIANCE WITH BOEHRINGER INGELHEIM

- Ablynx [Euronext Brussels: ABLX] today announced a two-year extension of the initial five-year research funding by Boehringer Ingelheim of their global strategic alliance to discover, develop and commercialise up to 10 different Nanobody® therapeutics. ... [ Publicerad 20 Mar 2012 av BolagsFakta ]

Entiteter: Ablynx, Boehringer Ingelheim GmbH, Edwin Moses, Claire Dickinson, Pipeline

Publicerad 14 Feb 2012 - uppdaterad 15 Feb 2012 - 2 Dokument

Edwin Moses

ABLYNX STRENGTHENS MANAGEMENT TEAM WITH THE APPOINTMENT OF DR ANDREAS MENRAD AS CHIEF SCIENTIFIC OFFICER

- Ablynx [Euronext Brussels: ABLX], today announced that it has appointed Dr Andreas Menrad as its Chief Scientific Officer. Dr Menrad has over 20 years experience in the pharmaceutical and biotech industry, with significant expertise in drug discovery ... [ Publicerad 14 Feb 2012 av BolagsFakta ]

Entiteter: Ablynx, Ledningsgrupp, Edwin Moses

Publicerad 01 Feb 2012 - uppdaterad 02 Feb 2012 - 1 Dokument

ABLYNX RECEIVES ANOTHER MILESTONE AS BOEHRINGER INGELHEIM SELECTS NANOBODY CANDIDATE FOR PRE-CLINICAL DEVELOPMENT (Ablynx)

- Ablynx [Euronext Brussels: ABLX] today announced that Boehringer Ingelheim has selected, as part of their strategic alliance, a second Nanobody® candidate for pre-clinical development, which triggered a €5 million milestone payment to Ablynx. The Nanobody ... [ Publicerad 01 Feb 2012 av BolagsFakta.se ]

Entiteter: Ablynx, Boehringer Ingelheim GmbH, Edwin Moses, Sue Charles, Merck Serono

Publicerad 23 Jan 2012 - uppdaterad 23 Jan 2012 - 1 Dokument

Ablynx

ABLYNX STATEMENT ON PRESS ARTICLE AND RELATED SHARE PRICE MOVEMENTS

- Ablynx [Euronext Brussels: ABLX] issued the following statement today. On Friday January 20th at 16.30 C.E.T., De Tijd, a Belgian newspaper, published online what was alleged to be a summary of a full article relating to Ablynx, scheduled to appear ... [ Publicerad 23 Jan 2012 av BolagsFakta ]

Entiteter: Ablynx, Edwin Moses, Börskurs

Publicerad 09 Jan 2012 - uppdaterad 10 Jan 2012 - 2 Dokument

JPMorgan Chase & Co

ABLYNX TO PRESENT PROGRESS IN 2011 AND ITS 2012 STRATEGY AT 30TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

- Ablynx [Euronext Brussels: ABLX] today announced that it will present a review of its progress in 2011, together with an outline of the Company's evolving strategy and a review of its portfolio and priorities for 2012, at the 30th Annual J.P. Morgan ... [ Publicerad 09 Jan 2012 av BolagsFakta.se ]

Entiteter: Ablynx, JPMorgan Chase & Co, Progress, Edwin Moses

Publicerad 04 Jan 2012 - uppdaterad 04 Jan 2012 - 2 Dokument

ABLYNX ANNOUNCES WEBCAST OF ITS PRESENTATION AT THE 30TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE (Ablynx)

- Ablynx [Euronext Brussels: ABLX] today announced that it plans to webcast its corporate presentation at the 30th Annual J.P. Morgan Healthcare Conference on Wednesday, 11 January 2012 at 03:30 p.m. PST / 00:30 a.m. CET. The presentation, followed by ... [ Publicerad 04 Jan 2012 av BolagsFakta.se ]

Entiteter: Ablynx, JPMorgan Chase & Co, Edwin Moses, Hälsovård

Pressreleaser

Sortera på: datum \| relevans
ABLYNX INITIATES A PHASE I STUDY FOR ALX-0651, ... [ Publicerad 29 Jun 2011 av Cision Wire ]
ABLYNX ANNOUNCES WEBCAST OF ITS PRESENTATION AT... [ Publicerad 31 May 2011 av Cision Wire ]